TARA (Protara Therapeutics) Earnings per share growth rate in current year
The high barrier to entry is driven by strict FDA control and the complexity of cell therapy patents. The YoY EPS dynamics on the GURU.Markets daily chart illustrate current trends, where -2.90 reflects the latest metric value for Protara Therapeutics (TARA). Monopoly pricing power is expected upon obtaining orphan drug status, while business development relies on academic partnerships without pursuing M&A.
Comprehensive metric breakdowns and analytics for Protara Therapeutics (TARA)
- stock price and consensus target price:
- business market valuation indicators:
- balance sheet equity data:
- debt and liquidity details:
Debt to Capital Protara Therapeutics|TARA - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio protaratx.com|TARA - Company Aggregate Debts|Debts to Book Capitalization Protara Tx|TARA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Protara Therapeutics|Quick Ratio protaratx.com
- financial results and valuation multiples details:
TARA - Net Income|Expected Net Income Protara Therapeutics|TARA - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Protara Tx|TARA - PEG Multiple|Business Value to Operating Income Before Depreciation Protara Tx|TARA - Operating profit EBITDA|Net earnings per one share for the last twelve months Protara Therapeutics|TARA - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months protaratx.com|TARA - Earnings growth in current year|Earnings growth forecast for next year Protara Therapeutics
- revenue and sales proceeds data:
Fundamental valuation:Protara Therapeutics
The market values Protara Therapeutics (TARA) through the lens of the monopoly potential of the TARA-002 drug, where inelastic demand for orphan therapy provides significant pricing power. By analyzing the year-over-year change in EPS, an investor can track earnings per share relative to the previous year, enabling a real-time assessment of the business's fundamental stability and the risk of asset impairment amid industry volatility.
Main competitors
BeiGene Ltd. - Earnings per share increase in current year|HALO (Halozyme Inc.) - Earnings growth in current year|Earnings per share growth rate in current year Revolution Medicines Corp RVMD|Earnings per share growth in current year Ascentage Pharma Group (AAPG)|CGON: Earnings per share trend in current year|Earnings per share growth in current year UroGen Pharma URGN|Earnings per share increase in current year BCAX|PSNL - Earnings per share growth in current year|Earnings per share growth rate in current year Erasca Oncology|DCTH (Delcath Systems, Inc.) - Net earnings per share growth this year|YMAB: Net earnings per one share growth for the current year|AURA (Aura Biosciences) - Earnings growth in current year|Earnings growth in current year Candel|Earnings per share growth in current year Accuray Inc. (ARAY)|SLS (sellaslifesciences.com) - Earnings per share increase in current year|Earnings growth in current year ACTU (Actuate Therapeutics, Inc.)|Earnings growth in current year citiusonc.com CTOR|HURA: Net earnings per share growth this year|Earnings per share increase in current year FATE (Fate Therapeutics Inc)|WHWK (aadibio.com) - Net earnings per share growth this year|TCRX: Net earnings per one share growth for the current year|CSBR (Champions Oncology Inc) - Earnings growth in current year|XBIT: Earnings per share increase in current year|Earnings growth in current year CVM|OSTX - Earnings per share growth rate in current year|Earnings per share growth in current year Radiopharm Theranostics RADX|Earnings per share increase in current year ARTV|Adlai Nortye Limited - Earnings growth in current year|VERU - Earnings growth in current year|Tempest Therapeutics, Inc. (TPST) - Earnings per share growth in current year|Earnings per share trend in current year XLO (Xilio Therapeutics)|RENB (Renovaro Biosciences) - Earnings growth in current year|Earnings per share growth rate in current year Mural Bio MURA|Net earnings per share growth this year KAPA (Kairos Pharma Ltd)|Earnings growth in current year onkuretherapeutics.com (OKUR)|CytoMed Therapeutics Limited - Net earnings per share growth this year|Net earnings per one share growth for the current year CRIS (Curis Inc.)|Apollomics Corp - Earnings growth in current year|Expected net earnings per share growth this year Tharimmune Corporation THAR|ADVB: Earnings growth in current year|Net earnings per share growth this year genprex.com|Earnings per share growth in current year Calidi Biotherapeutics Inc.|sunshinebiopharma.com (SBFM) - Expected net earnings per share growth this year|Net earnings per share growth this year XBIO (Xenetic Biosciences)|Net earnings per one share growth for the current year SLRX|Earnings growth in current year PPBT (Purple Biotech)|Earnings growth in current year American Oncology Network Inc AONC|BGNE - Earnings per share growth in current year|Earnings per share increase in current year CKPT (Checkpoint Therapeutics Inc.)|ELEV: Earnings growth in current year|iCAD (ICAD) - Earnings growth in current year|IKNA (Ikena Oncology Inc.) - Earnings growth in current year|Net earnings per share growth this year notablelabs.com (NTBL)|Earnings growth in current year VIRX|Earnings growth in current year MorphoSys Inc (MOR)|Earnings per share growth in current year NAYA Bio NAYA|AAPGV: Earnings per share growth this year
